AstraZeneca and Foundation Medicine Inc. will collaborate to develop companion diagnostic assays to identify patients most likely to benefit from medicines within AstraZeneca’s oncology pipeline. AstraZeneca will utilize the Quality Systems Regulations-compliant version of Foundation Medicine’s comprehensive genomic profiling assay for solid tumors to enroll patients into clinical trials of therapies that target genomically driven...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
